TITLE:
Dabigatran in the Treatment of Extensive Cerebral Venous Thrombosis: A Case Report
AUTHORS:
Viviane Maria Vedana, Luiz Carlos Porcello Marrone, Nathalia Guarienti Missima, William Alves Martins, Camila Simeoni, Luisa Franciscatto, Ricardo Bernardi Soder, Antônio Carlos Huf Marrone
KEYWORDS:
Cerebral Venous Thrombosis, Dabigatran, Non-Vitamin K Antagonist Oral Anticoagulant, Safety
JOURNAL NAME:
World Journal of Neuroscience,
Vol.8 No.1,
January
19,
2018
ABSTRACT: Background: Cerebral venous thrombosis (CVT) is a rare type of
cerebrovascular disease associated with a 15% rate of death or function
dependence. The mainstay of treatment for CVT is systemic anticoagulation,
despite venous hemorrhagic infarction. Vitamin K antagonists have long been the
only available option for anticoagulation; however, the past few years have
brought the development of many new target-specific drugs, collectively called
non-vitamin K antagonist oral anticoagulants (NOACs). Although emerging
evidence suggests NOACs have an acceptable safety and tolerability profile in
CVT, there are limited data available and no randomized controlled trials have
been performed to date. Case Presentation: This describes the case of a
patient with CVT occurring during an infection who was successfully treated
with a NOAC, dabigatran, after a difficult time on warfarin. Conclusions: A case of extensive and deep CVT was identified. Dabigatran
150 mg treatment twice daily in this patient resulted in no additional damage
to the brain. This case study illustrates that the use of NOACs such as
dabigatran can be safe and effective in patients with CVT.